Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Clinical trial NCT06006117 · RECRUITING
Trial details
- NCT number
- NCT06006117
- Sponsor
- The Lymphoma Academic Research Organisation
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-05
- Primary completion
- 2027-09-01
- Enrollment
- 260
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.